

ANIMAL CARE AND USE PROTOCOL Mahidol University-Institute Animal Care and Use Committee (MU-IACUC)

1	COVER SHEE	ĒΤ
2	Overview	
3	This section will be completed by the MU-IACUC	
	Protocol number	F01 -
	Date of submission (dd/mm/yy)	
	Date of Request modification (dd/mm/yy)	
	Date of Resubmitted (dd/mm/yy)	
	Date of Approved/Disapproved (dd/mm/yy)	
	Date of Expiration (dd/mm/yy)	
4	1. Protocol title:	
5	(Thai)	
6	(English)	
7	1.1 This protocol is a part of the main research	project entitled (if applicable)
8	(Thai)	
9	(English)	
10	1.2 Principal investigator of the main research p	roject (if applicable)
11	Name	
12	Position	Department
13	Faculty/Institute	
14	2. Principal investigator of the submitted protoco	ol: For a student thesis, principal
15	investigator is the principal adviser and student is a	a co-investigator
16	Name	
17	Position:Depart	ment
18	Faculty/Institute	
19	TelE-mail	
20	* Animal use license no	Expired date

*Issued by Institute of Animal for Scientific Purposes Development, NRCT

1

21

22	3. Co-investigators of the submitted protocol
23	3.1 Co-investigators directly involved with animals
24	3.1.1 Name
25	Position:Department
26	Faculty/Institute
27	TelE-mail
28	* Animal use license noExpired date
29	3.1.2 Name
30	Position:Department
31	Faculty/Institute
32	TelE-mail
33	* Animal use license noExpired date
34	3.2 Co-investigators NOT directly involved with animals
35	3.2.1 Name
36	Position:Department
37	Faculty/Institute
38	TelE-mail
39	3.2.2 Name
40	Position:Department
41	Faculty/Institute
42	Tel. <u>E</u> -mail
43	4. Contact person in case of emergency:
44	Name
45	Position:Department
46	Faculty/Institute
47	Work phoneMobile phone
48	E-mail
49	5. Type of animal protocol (may select more than one category)
50	Research: In the Field of
51	☐ Testing/Monitoring (please specify)
52	☐ Biological Production: (please specify)
53	☐ Animal Breeding (please specify)
54	Other (please specify)

55	6. Duration of Protocol:						
	Period for which the protocol is required	Years	Months				
	(must not exceed three years)						
	Start date	End date					
	Please submit your application one to two	months (pre	ferably two months) before	your			
	planned start date.						
56	(The start date has to be after the date of application submission. Please note that n						
57	animal use may occur until the Animal Ethic	s Committee	approves, and all animal u	se mus			
58	be finished before the end date. The date format is dd/mm/yyyy.)						
59	7. Funding source(s):						
60	☐ Received from						
61	Funding period from		to				
62	lue To be requested from						
63	Funding period from		to				
64	☐ Other, please specify						
65	8. Signatures Your signature as P.I., Co-in	vestigator or	this application verifies t	hat the			
66	information herein is true and correct and	-	, ,				
67	standard of animal care and use establish						
68	the Mahidol University and Office of the Na		•	_			
69	the Animal for Scientific Purpose Act., B.E. 2.		3				
70	Principal investigator:		Date				
71	(
72	Co- investigator:		Date				
73	()				
74	Co- investigator:		Date				
75	()				
76	The signature of Dean of Faculty /	Head of Ins	titute verifies that he / sh	e			
77	acknowledges the fact that P.I. under t	•	•				
78	and use protoco						
79	Head of Faculty/Institute:		Date				
80	()				
81	Faculty/Institute						

MAHIDOL UNIVERSITTY RESEARCH PROTOCOL FORMAT FOR PERMISSION OF ANIMAL CARE AND USE

82

r	of the project that is easily understood by non-scientists, expressing its significance and needs for undertaking the study).
	ationale and literature review: (Include a brief statement of the requirement for the
p	nformation being sought. Typically, the literature or the experience that led to the provided).
	iterature search for duplication: (This search must be performed to prevent
	Innecessary duplication of previous experiments). 3.1 Database(s) searched (Please specify the database name, e.g., PubMed, ScienceDirect):
	3.2 Date of literature search (must be within six months prior to submission date)
	3.3 Range of years searched (To prevent the duplication of your proposed experime the minimum period of search should be more than 5 years)
	3.5 Results of search: Does the proposed research duplicate any previous work? \[\sum_{\text{No}} \sum_{\text{Ves}} \text{ explain why it is scientifically necessary to duplicate previous experiments.} \]
4. C	Pbjective(s): (Provide goal/specific aim of this project)

6. Experimental	design and anir	mal procedures: F	Provide	a compl	ete, s	tep-by-s		
description of the	experiment(s). Des	cribe in detail the e	experime	ental proc	edures	s especio		
what will be done	from obtaining the	animals to the end	of anim	al experin	nent(s).	. Diagrar		
or flow chart(s) sh	ould accompany c	omplex experimento	al desig	n.				
7. Data analysis	and statistical m	nethods: Describe s	tatistica	al method	s to b	ne used		
1. Data dilatysis	and statistical in	ictious. Describe s	idistice	it method	<i>3 (0 0</i>	ie useu .		
analysis of the res	sults and for testing	the hypothesis						
, ,	, ,))						
8 Animal used a	nd justification:							
8. Animal used and justification:								
	-	ala in Tabla balaw						
	-	als in Table below	1	,		•		
	escription of anim		Age	Weight	Sex	Numb		
8.1 Provide de	-	als in Table below Strain/ Stock	Age	Weight	Sex	Numb		
8.1 Provide de	escription of anim		Age	Weight	Sex	Numb		
8.1 Provide de	escription of anim		Age	Weight	Sex	Numb		
8.1 Provide de	escription of anim		Age	Weight	Sex	Numb		
8.1 Provide de Common name	species	Strain/ Stock						
8.1 Provide de Common name 8.2 Permanen	species species	Strain/ Stock Od: (eg. ear tag, ear page)	punch,	microchip,	tattoo			
8.1 Provide de Common name 8.2 Permanen other please s	species species at animal ID methor	Strain/ Stock Od: (eg. ear tag, ear page)	punch,	microchip,	tattoo	o, N/A,		
8.1 Provide de Common name 8.2 Permanen other please s	species species at animal ID methor	Strain/ Stock Od: (eg. ear tag, ear page)	punch,	microchip,	tattoo	o, N/A,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co	species species at animal ID methor	Strain/ Stock od: (eg. ear tag, ear pecialized requirement)	punch, i	microchip, the resea	tattoo	o, N/A,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any)	species species at animal ID methor	Strain/ Stock Od: (eg. ear tag, ear page)	punch, i	microchip, the resea	tattoo	o, N/A,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any)	species species at animal ID methor	Strain/ Stock od: (eg. ear tag, ear pecialized requirement)	punch, i	microchip, the resea	tattoo	o, N/A,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any) 8.4 Source/Ve	species species at animal ID methors specify) specify) sensideration: (List specify)	Strain/ Stock od: (eg. ear tag, ear pecialized requirement	punch, i	microchip, the resec	tattoo	o, N/A, imals,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any) 8.4 Source/Ve Nature (Study on wildlife	species species at animal ID methor specify) consideration: (List seemedor:	Strain/ Stock od: (eg. ear tag, ear pecialized requirement) with the Wildlife Present	punch, and a servatic	microchip, the resea	tattoo	o, N/A, nimals,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any) 8.4 Source/Ve Nature (Study on wildlife B.E.2562(2019) ar	species species at animal ID methor specify) consideration: (List seemedor:	Strain/ Stock od: (eg. ear tag, ear pecialized requirement	punch, and a servatic	microchip, the resea	tattoo	o, N/A, nimals,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any)	species species at animal ID methor specify) consideration: (List seemedor:	Strain/ Stock od: (eg. ear tag, ear pecialized requirement) with the Wildlife Present	punch, and a servatic	microchip, the resea	tattoo	o, N/A, nimals,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any) 8.4 Source/Ve Nature (Study on wildlife B.E.2562(2019) ar	species species at animal ID methor specify) sinsideration: (List seemdor:	Strain/ Stock od: (eg. ear tag, ear pecialized requirement) with the Wildlife Present	punch, and a servatic	microchip, the resea	tattoo	o, N/A, nimals,		
8.1 Provide de Common name 8.2 Permanen other please s 8.3 Special co if any) 8.4 Source/Ve Nature (Study on wildlife B.E.2562(2019) ar please specify:	species species at animal ID methor specify) sendor: sendor: se must be comply to and National Parks A	Strain/ Stock od: (eg. ear tag, ear pecialized requirement) with the Wildlife Present Act B.E.2562(2019), P	punch, and a servatic	microchip, the resea	tattoo	n Act		

141	8.5 Explain why the proposed animal species is/are the most appropriate
142	
143	
144	8.6 Provide a statistical analysis for estimation of sample size with an explanation fo
145	the number of animals to be used
146	
147	
148	8.7 Transportation (if any, please specify how will the animals be transferred to the
149	lab)
150	8.8 Prevention of injury and/or infection
151	8.9 Is the quarantine required?
152	□ No
153	lacktriangle Yes, specify the method, location and duration
154	
155	
156	9. Animal care:
157	9.1 Husbandry consideration : (Briefly describe animal housing and living conditions,
158	routine animal observations, feed and water provisions, etc.)
159	9.1.1 Study location (specify room number, name of building or facility)
160	
161	
162	9.1.2 Housing system:
163	☐ Clean conventional ☐ Strict hygienic conventional
164	☐ Isolator maintained ☐ Barrier maintained
165	Laminar flow
166	Other, please specify
167	9.1.3 Caging:
168	☐ Solid bottom, open top ☐ Static filtered top cages
169	☐ Suspended cages, wire bottom ☐ Metabolic cages
170	☐ Individual ventilated cage (IVC)
171	Other, please specify
172	9.1.4 Cage size: W x L x H, (inch)
173	9.1.5 Caging materials:
174	Plastic Stainless steel
175	Other, please specify
176	9.1.6 Number of animals per cage:
177	

178	9.1.7 Social housing (more than one animal per cage):						
179	(The IACUC requires social housing of all social animals)						
180	☐ Yes ☐ No						
181	If NO, provide scientific justification for not socially housing the animals. Describe						
182	what will be done to replace this social contact with conspecifics.						
183							
184							
185	9.1.8 Environmental requirements:						
186	Temperature:						
187	Humidity:						
188	Light:						
189	Light cycle:						
190	9.1.9 Food						
191	Type of food:						
192	Feeding schedule: \square Routine feeding (ad libitum), \square Other, specify						
193	9.1.10 Water						
194	Type of water: \square Reverse osmosis, \square Other, specify						
195	Provision of water: \square Routine feeding (ad libitum), \square Other, specify						
196	9.1.11 Bedding						
197	□ No						
198	☐ Yes, please specify ☐ Sterile ☐ Non-sterile						
199	Type of bedding:						
200	☐ Paper ☐ Other, specify						
201	Schedule of changing: \square Once a week, \square Other, specify						
202	9.1.12 Environmental Enrichment:						
203	☐ Accept						
204	Decline, provide scientific justification						
205							
206	9.2 Is this project intended to conduct the animal experiment in other building?						
207	(This is allowed for conducting experiment(s) only not for housing. In addition, the						
208	holding period must be less than 12 hours).						
209	□ No —proceed to 10 □ Yes, answer all that apply in 9.2.1 to 9.2						
210	9.2.1 Where the experiment is expected to be conducted? Please indicate the						
211	building name and room number.						
212							
213	9.2.2 Please provide the animal experimental procedures in detail.						
214							
215	9.2.3 Estimated total time period that live animals will be kept in the laboratory ishours						

216	9.2.4 now witt the animal sample of Carcass be disposed?
	10. Veterinary medical care: (Describe the routine veterinary care. List the criteria used
218219	for health evaluation while the animals are on study).
220	
221	
222	11. Animal welfare:
223	11.1 Replacement, Reduction and Refinement. (Briefly describe how you have
224	considered each of the following alternatives (the 3Rs) or why they are not applicable).
225	11.1.1 Replacement of animals (e.g., with in vitro models, computer models or less
226	sentient animals)
227	
228	
229	11.1.2 Reduction in the number of animals (e.g., using appropriate statistical
230	methods in the design and analysis of the study; reduction in experimental
231	variability by using animals of defined genetic or microbiological status)
232	
233	11.1.2 Define the form with the large state of the state o
234	11.1.3 <u>Refinement of experimental procedures to minimize pain or distress</u> (e.g.,
235	early endpoints; use of analgesics, anesthetics or sedatives; techniques that reduce
236	stress in the animal.)
237	
238	
239	11.2 Potential animal pain and distress assessment:
240	11.2.1 Please indicate pain category according to USDA Pain and Distress. (Appendix A)
241	☐ Category B: Animals being bred or housed without any research manipulations
242	or non-invasive observation of animals in the natural habitat
243	Number of animals
244	☐ Category C: Animal use activities that involve no more than momentary or slight
245	pain or distress (no greater than an injection) where there is no need for use of
246	pain-relieving drugs
247	Number of animals
248	☐ Category D: Animal use activities that involve accompanying pain or distress to
249	the animals and for which appropriate anesthetics, analgesics, tranquilizing drugs,
250	and/or humane endpoints are used to avoid pain, distress, or discomfort
251	Number of animals

252	☐ Category E: Animal use activities that involve accompanying pain or distress to
253	the animals and for which appropriate anesthetic, analgesic, tranquilizing drugs;
254	or other methods for relieving pain or distress are NOT used
255	Number of animals
256	Provide strong scientific justification as to why pain-relieving drugs or other methods
257	for relieving pain cannot be used on animals.
258	
259	
260	11.2.2 During the study:
261	1) How often will the clinical condition of animals be monitored?
262	
263	2) Who will monitor the clinical condition of the animals?
264	
265	11.2.3 Are the animals expected to experience any specific study-induced or
266	related problems (i.e. health problems, pain, distress, complications, etc.) or any
267	health problems as a result of the phenotype of the animal?
268	☐ No —proceed to 12 ☐ Yes, answer all that apply in 11.2.3.1 to 11.2.3.2
269	11.2.3.1 Describe the expected problems.
270	
271	11.2.3.2 What criteria(s) will be used to assess pain, distress, or discomfort? Check all that
272	apply:
273	☐ Inactivity
274	Loss of appetite
275	Loss of weight \square 5% \square 10 % \square 15% \square 20% weight loss
276	Restlessness
277	Abnormal resting postures, somnolence or hunched posture
278	Licking, biting, scratching, or shaking a particular area
279	Failure to show normal patterns of inquisitiveness
280	Failure to groom, causing and unkempt appearance
281	Guarding (protecting the painful area)
282	Loss of mobility
283	\square Red stain around the eyes of rats
284	☐ Self-mutilation
285	☐ Labored breathing
286	
287	Unresponsiveness
288	Other (please list)
289	11.2.4 Literature search for alternative to procedure that cause pain & distress
290	11.2.4.1 Date of literature search (must be within six months prior to submission
291	date) (<i>dd/m/yy</i>))

292	11.2.1.2 Range of years searched (To prevent the duplication of your proposed
293	experiment, the minimum period of search should be more than 5 years)
294	
295	11.2.1.3 Key words used in search:
296	11.2.1.4 Results of search: Does the proposed research duplicate any previous work?
297	□ No □ Yes
298	If YES, explain why it is scientifically necessary to duplicate previous experiment.
299	
300	
301	11.3 Anesthesia
302	☐ No ☐ Yes, please answer the following questions:
303	1) Preanesthetic preparation:
304	2) Anesthetic agent(s) used:
305	3) Dosage:
306	4) Volume:
307	5) Route of administration:
308	6) Frequency of anesthesia:
309	7) Length of anesthesia:
310	8) Who is responsible for monitoring anesthesia?
311	9) If an inhalation anesthetic is used, describe scavenging of the waste anesthetic gas.
312	
313	10) What criteria(s) will be used to assess level of anesthesia?
314	
315	Check all that apply:
316	\square Respiration rate \square Body temperature \square Heart rate
317	☐ ECG ☐ Toe pinch ☐ Tail pinch
318	☐ Corneal reflex ☐ Pedal reflex ☐ Muscular relaxation
319	☐ Color of mucous membrane
320	☐ Other (pulse oximeter, respirometer) please list
321	11) How animals are kept warm?
322	11.4 Analgesics and/or tranquilizers:
323	☐ No ☐ Yes, please specify
324	1) Type of analgesics used
325	Agent(s)
326	2) Dosage
327	3) Route of administration
328	4) Schedule
329	11.5 Describe post-anesthetic treatment or intervention:
330	
331	

332	12. Surgery:						
333	☐ No —procee	d to 13	☐ Yes, answer	all that	apply in 1.	2.1 to 12.7	
334	12.1 Surgical pr	ocedure is	: Non-	-survival	□ S	urvival	
335			□ Мајо	or		1inor	
336			☐ One	time		Multiple	
337	12.2 Location: (Give the lo	cation/room n	umber f	or the prop	oosed surgical	orocedure.)
338							
339	12.3 Surgeon/q	ualificatior	n: (Indicate wh	o will pe	erform the s	surgery, and hi	s/her
340	qualifications, tr	aining, or e	xperience in ti	he propo	osed proced	dure.)	
341		_					
342 343	12.4 Procedure:			,			
344	12.5 Pre- and p						
345 346	post-operative c	are, includ	ing provisions	for post-	-surgical ob	servation.)	
347	12.6 Describe lo	ong-term c	are of chronic	surviva	al procedu	 re	
348	12,0 5050,150 (21.5 (01.1.1 0		3 34. 1.10	at p. occuu		
349	12.7 Multiple sur	vival surgen	v procedures: (/	Multiple i	maior opera	tive procedures	on the same
350	animal must be a		-	•	•	•	
351		, , , ,	-	-			_
352							
353						and treatment	
354			· 				
355	13. Blood or body	fluid witho	drawal/tissue (collectio	on/injection	ns, tail clip, Ga	avage
356	(Describe in deta	il: method(s), needle size	(s), volui	me(s) colle	cted or admini	istered, and
357	frequency of co	llection or	injection.)				
	Procedures	Anatomic	Needle size/	Biopsy	Volume	Volume	Frequency
		location	catheter size	size	collected	administered	
	81 1 111 1		and length		(ml)	(ml)	
	Blood withdrawal						
	Body Fluid withdrawal						
	Tissue collection						
	Injection						
	Infusion						
	Tail clip						
	Gavage						
	Other (specify)						
358	Total blood volu	ıme	ml. in	total _	stuc	dy days or	months

359	14. Use of non-phari	maceutical	grade com	pounds				
360	14.1 Will animals	14.1 Will animals be treated with non-pharmaceutical grade compounds?						
361	□ No —proceed to 15							
362	☐ Yes, answe	\square Yes, answer all that apply in 14.1 and 14.2						
363	14.2 Give informa	14.2 Give information on name, source, formulation, concentration, site and route						
364	of administration	of administration and potential side effects						
365								
366								
367	14.3 Provide sc	ientific jus	tification	for the use of	non-pharma	ceutical grad		
368	compounds							
369								
370								
371	15. Restraint with me	echanical d	evices:					
372	☐ No —proce	ed to 16	☐ Yes,	answer all that a	pply in 15.1 ar	nd 15.2		
373	15.1 Describe de	vice, durati	on of restra	aint, frequency o	f observation,	conditioning		
374	procedures and	steps to ass	sure comfo	rt and well-being				
375								
376								
377	15.2 Provide scie	ntific justifi	cation for _l	prolonged compl	ete restraint			
378								
379								
	1.C. Duntant to calcity	f a al a al .		4				
380	16. Project involving		-	•	-			
381	16.1 Does this pr	otocol invo	ive rood o	r water deprivation	on or dietary r	nanipulation		
382	☐ No—proce	ed to 17						
383	☐ Yes, <i>descri</i>	ibe method.	s for assess	sing physical cond	litions (e.g., we	ight loss), pair		
384	discomfort and	d stress duri	ng the cour	se of study. Includ	le clinical signs	and symptom		
385	expected.							
386								
387								
388	16.2 Provide deta	ail of these	procedure	s in Table below				
	Procedures	Amount	Duration	Compound	Compound	Frequency		
		restricted		supplemented	excluded			
		or added						
	Food deprivation							
	Fluid deprivation							
	Nutrient alteration							
389								

390	17. Tumor study, use of disease models and toxicity testing
391	17.1 Does this protocol involve tumor study, use of disease models or toxicity
392	testing?
393	□ No—proceed to 18
394	lacktriangle Yes, answer all that apply in 17.2 and 17.3
395	17.2 Describe methods for assessing physical conditions, stress, pain and
396	discomfort during the course of study. Include clinical signs and symptoms expected.
397	
398	
399	17.3 What are the criteria for humane endpoint in this protocol?
400 401	
402	18. Behavioral studies:
403	18.1 Does this protocol involve behavioral study?
404	□ No—proceed to 19
405	Tes, answer all that apply in 18.2 to 18.3
406	18.2 Describe type of behavioral manipulation
407	
408 409	18.3 Describe the protocol involving the use of testing apparatus or aversive stimulus
410	and detail of duration and frequency of the testing period
411	
412	19. Study endpoints
413	19.1 Describe the endpoint for the animals in this protocol. Indicate whether recovery,
414	euthanasia, or death is/are expected, and when the animal experimentation phase will be
415	stopped.
416	
417	
418	19.2 Humane (early) endpoint is used (i.e., animals are humanely euthanized prior to
419	the expected day of termination)
420	□ No
421	☐ Yes, provide criteria for humane endpoint
422	
423	
424	19.3 Death or moribund as an endpoint is used
425	□ No —proceed to 20
426	Tes, answer all that apply in 19.3.1 to 19.3.2

427	19.5.1 Provide Criteria that establish when this er	iupoint has bee	n reached, and	
428	describe how animals will be monitored and cared for			
429				
430	19.3.2 List persons responsible for evaluating ani	mal condition, r	ecord keeping, a	nd
431	notifying PI and/or veterinarians to perform euth	anasia		
432				
433	20. Animal euthanasia and disposition			
434	20.1 After completion of activity, the animals will	l be:		
435	☐ Euthanized			
436	☐ Returned to production/breeding unit/facility	inventory		
437	\square Transferred to another research project:			
438	 Protocol No and name of princ 	cipal		
439	Other, specify			
440	20.2 Describe the two-step euthanasia method acc	cording to AVMA	A guidelines	
441	This protocol uses:			
442	Step 1 - Describe chemical method:			
443	☐ Immersion:			
444	☐ Pharmaceutical-grade clove oil at	ml/L for	minutes	
445	☐ MS-222 at	mg/L for	minutes	
446	☐ Magnesium salts at	mg/L for	minutes	
447	☐ Ethanol at%	ml/L for	minutes	
448	2-phenoxyethanol at	ml/L for	minutes	
449	☐ Benzocaine at	mg/L for	minutes	
450	Lidocaine at	mg/L for	minutes	
451	☐ Isoflurane at	mg/L for	minutes	
452	☐ Sevoflurane at	mg/L for	minutes	
453	Quinaldine sulfate at	mg/L for	minutes	
454	\square Other, specify			
455	☐ Injection:			
456	☐ Pentobarbital at	mg/	kg	
457	☐ Ketamine at			
458	☐ Ketamine-medetomidine at			
459	$lacksquare$ Other, specify at _			
460	Route of administration	J		
461	☐ Intramuscular, ☐ Intravenous, ☐	Intraperitoneal	, \square Intracoelo	mic
462	☐ Intracardiac			

Step 2 - Describe mechanical method:
☐ Cervical transection
\square Chilling using: \square Ice, \square Cold water for minutes
☐ Cranial concussion
☐ Decapitation
☐ Exsanguination
☐ Maceration
☐ Penetrating captive bolt
☐ Pithing
Other mechanical method, specify
\square Use another method besides mechanical method, describe and provide strong
scientific justification
20.3 State how death will be verified before disposal:
21. Necropsy/ Selected tissue and sample collection
□ No
☐ Yes, provide room number, personnel with qualification
22. Animal sample utilization and disposal:
22.1 Subsequent use of animal samples, when the primary research is completed, are any
remaining animal samples used for other proposes?
□ No
\square Yes, please describe the specific parts and purpose(s), such as archival for future
studies, inclusion in a teaching collection, donation to a museum, etc.
22.2 Animal tissue and carcasses disposal: Describe method used to dispose animal tissue
and carcasses.
23. Occupational health and safety:
23.1 Select types of hazards associated with this protocol, also provide name, source
and amount to be used in each category
☐ Cancer cell lines
• • ITHER HALL ADEALS DIGWIN THO CONTINUOUS OF NOCOTOTAL OPPROVAL

501				
502	Hazardous chemicals (e.g., carcinogen, mutagen and teratogen)			
503				
504	Recombination agents			
505				
506	□ None			
507		cify biosafety level: D BSI		
508	-	ain how the wastes associate	ed with these	hazards are decontaminated and
609	disposed			
510				
11		ain how the carcasses assoc		se hazards are disposed
513	-			•
514				
515				e measures (e.g., biosafety cabinet
516				hazards and list any surveillance
517		es in place to monitor any po		· ·
518	•		·	
519				
520	23.6 ln ca	ase of accident, provide imm	nediate proced	lures and early treatment to limit
21	possible	injury or illness		
522				
	04 Ovelifica	· · · · · · · · · · · · · · · · · · ·		
23		tion of personnel:	· invalved with	the animals on this project
24		dividuals who will be <u>directly</u> Il investigators, students, pos		
25 ne		,		archers, staff research associates at the animals. If personnel do not
26		,		the animals. IJ personnel ao nol
27		erience, state how they will b	1	<u> </u>
	Name	Responsibilities	Direct	Relevant experience and
			involvement	qualification
			with animal samples (%)	(e.g. How many years of experience working with animals
			Samples (70)	or training related to the research)
				of training related to the research,

As Principal investigator on this protocol, I verifies that the information herein is true and 528 correct and that I am familiar with and will comply with standard of animal care and use 529 established under the ethical guidelines and policies of Mahidol University, and Office of the 530 National Research Council of Thailand (NRCT). Additionally, I acknowledge my 531 responsibilities and provide assurances for the followings: 532 A. Animal use: The animals authorized for use in this protocol will be used only in the 533 activities and in the manner described herein, unless a deviation is specifically approved by 534 the MU-IACUC. 535 B. Duplication of effort: I have made a reasonable, good faith effort to ensure that this 536 protocol is not an unnecessary duplication of previous experiments. 537 C. Statistical assurance: I assure that I have consulted with qualified statistician to evaluate 538 the statistical design or strategy of this proposal, and that the minimum number of animals 539 needed for scientific validity are used. 540 D. Biohazard/safety: I have taken into consideration, and I have made the proper 541 coordination's regarding all applicable rules and regulations concerning radiation protection, 542 biosafety, recombinant issues, etc., in the preparation of this protocol. 543 E. Training: I verify that the personnel performing the animal procedures/manipulations described in this protocol are technically competent and have been properly trained to ensure 545 that no unnecessary pain or distress will be caused as a result of the procedures/manipulations. 546 F. Responsibility: I acknowledge the inherent moral and administrative obligations associated 547 with the performance of this animal use protocol, and I assure that all individuals associated with 548 this project will demonstrate a concern for the health, comfort, welfare, and well-being of the 549 research animals. Additionally, I pledge to conduct this study in the responsibility for 550 implementing animal use alternatives where feasible, and conducting humane and lawful 551 research. 552 G. Scientific review: This proposed animal use protocol has received appropriate peer 553 scientific review, and is consistent with good scientific research practice. 554 H. Research studies: 555 ☐ This protocol is associated with a grant application. I certify that this protocol is 556 essentially the same as the study found in the grant application or program/project. 557 The MU-IACUC and the funding agency will be notified of any changes in the proposed 558 project, or personnel, relative to this application. I will not proceed with animal 559 experiment until approval by the MU-IACUC is granted. 560 ☐ This protocol is not associated with a grant application. 561

Principal investigator _____ Date ____

(______)

562

563

564 Appendix A

USDA Pain Levels:

565566

567

USDA Category B	USDA Category C	USDA Category D	USDA Category E
Breeding or Holding Colony Protocols	No more than momentary or slight pain or distress and no use of pain-relieving drugs, or no pain or distress. For example: euthanatized for tissues; just observed under normal conditions; positive reward projects; routine procedures; injections; and blood sampling.	Pain or distress appropriately relieved with anesthetics, analgesics and/or tranquilizer drugs or other methods for relieving pain or distress.	Pain or distress or potential pain or distress that is <u>not</u> relieved with anesthetics, analgesics and/or tranquilizer drugs or other methods for relieving pain or distress.
	Examples	Examples	Examples
	 Holding or weighing animals in teaching or research activities. Injections, blood collection or catheter implantation via superficial vessels. Tattooinganimals. Ear punching of rodents. Routine physical examinations. Observation of animal behavior. Feeding studies, which do not result in clinical health problems. AVMA approved humane euthanasia procedures. Routine agricultural husbandry procedures. Live trapping. Positive reward projects. 	 Diagnostic procedures such as laparoscopy or needle biopsies. Non-survival surgical procedures. Survival surgical procedures. Post-operative pain or distress. Ocular blood collection in mice. Terminal cardiac blood collection. Any post procedural outcome resulting in evident pain, discomfort or distress such as that associated with decreased appetite/ activity level, adverse reactions, to touch, open skin lesions, abscesses, lameness, conjunctivitis, corneal edema and photophobia. Exposure of blood vessels for catheter implantation. Exsanguination under anesthesia. Induced infections or antibody production with appropriate anesthesia and post-op/post-procedure analgesia when necessary. 	 Toxicological or microbiological testing, cancer research or infectious disease research that requires continuation until clinical symptoms are evident or death occurs. Ocular or skin irritancy testing. Food or water deprivation beyond that necessary for ordinary pre-surgical preparation. Application of noxious stimuli such as electrical shock if the animal cannot avoid/escape the stimuli and/or it is severe enough to cause injury or more than momentary pain or distress. Infliction of burns or trauma. Prolonged restraint. Any procedures for which needed analgesics, tranquilizers, sedatives, or anesthetics must be withheld for justifiable study purposes. Use of paralyzing or immobilizing drugs for restraint. Exposure to abnormal or extreme environmental conditions. Psychotic-like behavior suggesting a painful or distressful status. Euthanasia by procedures not approved by the AVMA.

(Note: there is no USDA Category A.)

Guidelines for determining USDA classification in protocols involving tissue collection before/after euthanasia and/or animal perfusion:

If an animal will be euthanatized by an approved physical or chemical method of euthanasia solely for the collection of tissues (after the animal's death), the procedure should be classified as USDA C.

If an animal will be anesthetized so that non-vital tissues can be collected (liver or skin biopsy), and the animal will then be allowed to recover, the procedure should be classified as USDA D (survival surgery).

If an animal will be anesthetized so that non-vital tissues can be collected (liver or skin biopsy, etc.); and the animal will then be euthanatized, the procedure should be classified as USDA D (non-survival surgery). In this scenario, it is necessary to justify why the animal couldn't be euthanatized (USDA category C) rather than anesthetized.

If an animal will be anesthetized so that vital tissues can be collected (heart, both kidneys or lungs, whole liver, etc.), the animal will obviously succumb to the procedure. To determine whether this will be euthanasia or non-survival surgery, we must consider the definition of euthanasia. A critical component of this definition is "rapid unconsciousness followed by loss of cardiac, respiratory and brain function". Based on this definition, procedures which require tissue manipulation or other prolonged techniques prior to the animals death (more than a few minutes) should be classified as non-survival surgery (USDA D). Similarly, if an animal will be anesthetized so that the tissue can be collected in the "freshest" possible state (i.e. heart) and the tissues will be rapidly excised, the procedure should be classified as euthanasia (USDA C). (Note: In this scenario, it is difficult to justify why the animal couldn't be euthanatized rather than anesthetized.)

If an animal will be anesthetized so that it can be chemically perfused, the same "test of time" applies (i.e.: long, technical manipulations should be classified as USDA D; while rapid intravascular injection of the perfusate without other manipulations should be classified as USDA C).

NOTE: Because the USDA classification system is based on the "potential for pain, distress or discomfort" the anesthetic/euthanasia drug dose becomes a critical concern. For example, if a known "euthanasia dose" of pentobarbital will be administered, drug irreversibility is assumed. Thus, once the animal is confirmed to be in an anesthetic plane (toe pinch response, etc.), tissues can be collected/ procedures can be performed without the concern about what the animal will be perceiving. This procedure would then be classified as USDA C. The Committee recommends using a euthanizing dose whenever possible. Other methods may be appropriate with proper scientific justification.